A 10-Year Retrospective Cohort Study of Real-World Effectiveness of Sofosbuvir-Based Regimens for Hepatitis C in a Single Center in China

Abstract

Abstract This study aimed to review the trends of hepatitis C virus (HCV) treatment over the past decade and to analyze the effectiveness of sofosbuvir (SOF)–based direct-acting antiviral regimens in the heterogeneous population of patients with chronic hepatitis C (CHC) in clinical practice. This retrospective cohort study included CHC patients attending the Sir Run Run Shaw Hospital between January 1, 2012, and December 31, 2022. All of the 194 patients treated with SOF-based regimens completed 12 weeks of treatment and were followed up for at least 12 weeks after completion of the therapy. Sustained virologic response (SVR) 12 weeks after the end of treatment was the primary endpoint. A total of 194 patients treated with SOF-based regimens were included, among which 121, 56, 10 and 7 patients received SOF + velpatasvir ± ribavirin, SOF + daclatasvir, SOF + ledipasvir or SOF + ribavirin, respectively. With 36.1%, HCV Genotype 1 predominated in CHC patients treated with SOF-based regimens, followed by Genotype 2a with 17.5% and Genotype 3 with 14.9%. Comorbidities among patients included hypertension (4.1%), diabetes (2.1%), depression (1.0%) and neoplastic disease (2.6%). All patients treated with SOF-based regimens achieved SVR. There was no association between SVR and factors such as HCV genotype, sex, age, presence of cirrhosis or previous treatment history. There were no reports of any serious adverse events in the study. This single-center retrospective study represented the latest 10-year treatment trends for HCV in real-world clinical practice and provided useful information on the excellent efficacy of SOF-based direct-acting antiviral regimens for treatment of CHC patients in Eastern China.